Illumina Inc
F:ILU
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
62.29
132.28
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Illumina Inc
In the world of genomics, Illumina Inc. stands as a pioneer, reshaping the landscape of genetic sequencing with a precision that borders on artistry. This San Diego-based company, founded in 1998, has become an industry cornerstone by unlocking the potential of the human genome through its advanced sequencing technologies. Illumina's success is anchored in its innovative creation of next-generation sequencing platforms, which enable researchers to analyze DNA at a scale and speed previously thought impossible. By providing the tools that sequence, analyze, and interpret vast amounts of genetic data, Illumina plays a crucial role in driving discoveries in personalized medicine, agriculture, and countless other fields.
At the heart of Illumina's business model lies its suite of sequencing instruments and consumables, which form the backbone of its revenue generation. Their sequencing machines, ranging from behemoth instruments capable of cracking the human genome to compact devices used for focused applications, operate much like a razor-and-blade model. Once customers invest in Illumina's platforms, they continue to purchase consumable products, including reagents and advanced software, crucial for each sequencing run. This model not only fosters continuous engagement with their user base but also sustains a steady revenue stream. By expanding its reach into genomic-based clinical applications, Illumina has also started tapping into diagnostic markets, promising to transform the future of healthcare while ensuring sustained growth for the company.
In the world of genomics, Illumina Inc. stands as a pioneer, reshaping the landscape of genetic sequencing with a precision that borders on artistry. This San Diego-based company, founded in 1998, has become an industry cornerstone by unlocking the potential of the human genome through its advanced sequencing technologies. Illumina's success is anchored in its innovative creation of next-generation sequencing platforms, which enable researchers to analyze DNA at a scale and speed previously thought impossible. By providing the tools that sequence, analyze, and interpret vast amounts of genetic data, Illumina plays a crucial role in driving discoveries in personalized medicine, agriculture, and countless other fields.
At the heart of Illumina's business model lies its suite of sequencing instruments and consumables, which form the backbone of its revenue generation. Their sequencing machines, ranging from behemoth instruments capable of cracking the human genome to compact devices used for focused applications, operate much like a razor-and-blade model. Once customers invest in Illumina's platforms, they continue to purchase consumable products, including reagents and advanced software, crucial for each sequencing run. This model not only fosters continuous engagement with their user base but also sustains a steady revenue stream. By expanding its reach into genomic-based clinical applications, Illumina has also started tapping into diagnostic markets, promising to transform the future of healthcare while ensuring sustained growth for the company.
Revenue Beat: Illumina reported Q3 revenue of $1.08 billion, coming in above the top end of their guidance range and returning to growth outside China.
Margin Strength: Non-GAAP operating margin expanded to 24.5%, up 190 basis points year-over-year, and non-GAAP diluted EPS rose to $1.34, both above guidance.
Raised 2025 Guidance: Management increased full-year 2025 revenue and EPS guidance, now expecting $4.27–4.31 billion in revenue and non-GAAP EPS of $4.65–$4.75.
NovaSeq X Transition: Over 75% of high-throughput sequencing volume and 51% of revenue are now on the NovaSeq X platform, exceeding transition targets.
Clinical Growth: Clinical sequencing consumables revenue grew at a double-digit rate outside China, driven by new assay approvals and expanding test adoption.
China Resilience: Despite export restrictions, China revenue outperformed expectations; management remains cautious about long-term China outlook.
Margin Expansion Outlook: Executives expressed confidence in further margin improvement, citing ongoing cost discipline and operational leverage.
Muted Research Demand: Research end markets remain soft due to funding uncertainties, though pricing headwinds are expected to ease as the NovaSeq X transition completes.
